Literature DB >> 9300670

CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation.

H C DeGrendele1, M Kosfiszer, P Estess, M H Siegelman.   

Abstract

A defining juncture in the life of a T cell is its encounter with its cognate Ag, resulting finally in effector and/or memory T cells known to express, among other characteristics, increased surface levels of CD44. The requirements for the "activation" of CD44 to bind its major ligand, hyaluronan (HA), and the in vivo role of this interaction remain unresolved. We have recently proposed that the CD44/HA interaction is involved in primary lymphocyte adhesion, leading to extravasation at inflammatory sites. We show here that activation of CD44 and ability to engage in rolling occurs directly through polyclonal as well as Ag-specific TCR-initiated signaling. Using a superantigen, it is primarily the Ag-specific activated Vbeta-bearing cells that are induced to bind HA. In addition, this CD44 activation does not appear to be the result of overt changes in glycosylation. These results connect activation of CD44 on T cells with the initiation of immune responses and suggest potential roles for the CD44/HA interaction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9300670

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Significance of VLA-4-VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model.

Authors:  T Okada; R G Hawley; M Kodaka; H Okuno
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

Review 2.  Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow.

Authors:  Alexander Zarbock; Klaus Ley; Rodger P McEver; Andrés Hidalgo
Journal:  Blood       Date:  2011-10-20       Impact factor: 22.113

3.  Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes.

Authors:  Daniela I M Loeffler; Christoph U Schoen; Werner Goebel; Sabine Pilgrim
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Multifaceted regulation of T cells by CD44.

Authors:  Bas Jg Baaten; Cheng-Rui Li; Linda M Bradley
Journal:  Commun Integr Biol       Date:  2010-11-01

5.  Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion.

Authors:  M Mohamadzadeh; H DeGrendele; H Arizpe; P Estess; M Siegelman
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

6.  RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy.

Authors:  Shlomo Nedvetzki; Erez Gonen; Nathalie Assayag; Reuven Reich; Richard O Williams; Robin L Thurmond; Jing-Feng Huang; Birgit A Neudecker; Fu-Sheng Wang; Fu-Shang Wang; Eva A Turley; David Naor
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-13       Impact factor: 11.205

Review 7.  The physics of cancer: the role of physical interactions and mechanical forces in metastasis.

Authors:  Denis Wirtz; Konstantinos Konstantopoulos; Peter C Searson
Journal:  Nat Rev Cancer       Date:  2011-06-24       Impact factor: 60.716

8.  Marginal zone B-cell depletion impairs murine host defense against Borrelia burgdorferi infection.

Authors:  Alexia A Belperron; Catherine M Dailey; Carmen J Booth; Linda K Bockenstedt
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

9.  Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium.

Authors:  Rahima Zennadi; Ai Chien; Ke Xu; Milena Batchvarova; Marilyn J Telen
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

10.  Renal proximal tubular epithelial cell transforming growth factor-beta1 generation and monocyte binding.

Authors:  Xiao Liang Zhang; Wisam Selbi; Carol de la Motte; Vincent Hascall; Aled Phillips
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.